https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e1191732
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e11917322016-05-31 00:00:002020-11-30 10:28:30Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-862016-05-07 00:00:002019-02-15 08:39:08Dendritic cell-based cancer immunotherapy for colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-03 / Biomedicines 2016 May;4(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-03 / Biomedicines 2016 May;4(2)2016-05-03 00:00:002016-05-03 00:00:00Cancer Vaccines in Ovarian Cancer: How Can We Improve?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-01 / Am. J. Respir. Crit. Care Med. 2016 05;193(9):1023-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-01 / Am. J. Respir. Crit. Care Med. 2016 05;193(9):1023-312016-05-01 00:00:002020-09-07 08:01:30Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-21 / Radiat Oncol 2016 Apr;11:60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-21 / Radiat Oncol 2016 Apr;11:602016-04-21 00:00:002019-02-15 08:45:46Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-906
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-9062016-04-15 00:00:002019-02-15 08:45:11Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-11 / Cancer Res. 2016 06;76(12):3496-506
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-11 / Cancer Res. 2016 06;76(12):3496-5062016-04-11 00:00:002019-02-15 08:49:43T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-07 / Tumour Biol. 2016 Aug;37(8):11267-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-07 / Tumour Biol. 2016 Aug;37(8):11267-782016-03-07 00:00:002019-02-15 08:47:52Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra272016-03-02 00:00:002022-09-29 14:06:28Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-01 / J. Acquir. Immune Defic. Syndr. 2016 Mar;71(3):246-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-01 / J. Acquir. Immune Defic. Syndr. 2016 Mar;71(3):246-532016-03-01 00:00:002019-02-15 08:48:03Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial
